Comparative evaluation of 177Lu-DOTATATE and 90Y-DOTATATE in SSTR II overexpressing Xenograft models for treatment of variable volume neuroendocrine tumours

被引：0
|
作者：
Tawate, Megha [1 ]
Sahu, Sudeep [2 ]
Chakraborty, Avik [2 ]
Lad, Sangeeta [2 ]
Gaikwad, Sujay [2 ]
Mitra, Arpit [3 ]
Upadhye, Trupti [2 ]
Menon, Sreeja [2 ]
Damle, Archana [2 ]
Banerjee, Sharmila [1 ,4 ]
机构：
[1] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Navi Mumbai, India
[2] Bhabha Atom Res Ctr, Mumbai, Maharashtra, India
[3] Board Radiat & Isotope Technol, Navi Mumbai, India
[4] Homi Bhabha Natl Inst, Mumbai, Maharashtra, India
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2022年 / 108卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P-302
引用
收藏
页码：S213 / S214
页数：2
相关论文
共 50 条
  • [41] Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
    Lisa Bodei
    Marta Cremonesi
    Mahila Ferrari
    Monica Pacifici
    Chiara M. Grana
    Mirco Bartolomei
    Silvia M. Baio
    Maddalena Sansovini
    Giovanni Paganelli
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35 : 1847 - 1856
  • [42] Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors
    Bodei, Lisa
    Cremonesi, Marta
    Ferrari, Mahila
    Pacifici, Monica
    Grana, Chiara M.
    Bartolomei, Mirco
    Baio, Silvia M.
    Sansovini, Maddalena
    Paganelli, Giovanni
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (10) : 1847 - 1856
  • [43] Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study
    Kunikowska, Jolanta
    Pawlak, Dariusz
    Bak, Marianna I.
    Kos-Kudla, Beata
    Mikolajczak, Renata
    Krolicki, Leszek
    [J]. ANNALS OF NUCLEAR MEDICINE, 2017, 31 (05) : 347 - 356
  • [44] Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study
    Jolanta Kunikowska
    Dariusz Pawlak
    Marianna I. Bąk
    Beata Kos-Kudła
    Renata Mikołajczak
    Leszek Królicki
    [J]. Annals of Nuclear Medicine, 2017, 31 : 347 - 356
  • [45] Outcome prediction in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT): results from a prospective phase II clinical trial
    Mileva, M.
    Marin, G.
    Levillain, H.
    Artigas, C.
    Van Bogaert, C.
    Marin, C.
    Danieli, R.
    Deleporte, A.
    Jungels, C.
    Vanderlinden, B.
    Wimana, Z.
    Hendlisz, A.
    Flamen, P.
    Karfis, I.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S106 - S106
  • [46] Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)
    Braat, Arthur J. A. T.
    Kwekkeboom, Dik J.
    Kam, Boen L. R.
    Teunissen, Jaap J. M.
    de Herder, Wouter W.
    Dreijerink, Koen M. A.
    van Rooij, Rob
    Krijger, Gerard C.
    de Jong, Hugo W. A. M.
    van den Bosch, Maurice A. A. J.
    Lam, Marnix G. E. H.
    [J]. BMC GASTROENTEROLOGY, 2018, 18
  • [47] Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)
    Arthur J. A. T. Braat
    Dik J. Kwekkeboom
    Boen L. R. Kam
    Jaap J. M. Teunissen
    Wouter W. de Herder
    Koen M. A. Dreijerink
    Rob van Rooij
    Gerard C. Krijger
    Hugo W. A. M. de Jong
    Maurice A. A. J. van den Bosch
    Marnix G. E. H. Lam
    [J]. BMC Gastroenterology, 18
  • [48] Long-Term Follow-Up of Advanced Paraganglioma Patients Treated With 177Lu-Dotatate or 90Y-Dotatoc PRRT in Phase-II Perspective Protocols: Activity And Toxicity Reports
    Severi, S.
    Zovato, S.
    Di Mauro, F.
    Ferrara, A. M.
    Nicolini, S.
    Tardelli, E.
    Bongiovanni, A.
    Di Iorio, V.
    Mezzenga, E.
    Scarpi, E.
    Turri, V.
    Paganelli, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S185 - S185
  • [49] Safety and organs-at-risk dosimetry in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT): data from prospective phase II clinical trial
    Mileva, M.
    Van Bogaert, C.
    Marin, G.
    Levillain, H.
    Artigas, C.
    Marin, C.
    Danieli, R.
    Deleporte, A.
    Jungels, C.
    Vanderlinden, B.
    Wimana, Z.
    Hendlisz, A.
    Flamen, P.
    Karfis, I.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S103 - S103
  • [50] Availability of both [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?
    Basu, Sandip
    Parghane, Rahul V.
    Banerjee, Sharmila
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) : 756 - 758
12345